Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples

Journal of Virological Methods

Volumn 183, Issue 1, 2012, Pages 14-18

  Cañadas, María Paz ^a,b   Cirigliano, Vincenzo ^b   Darwich, Laila ^a,c   Sirera, Guillermo ^d,e   Coll, Josep ^d,e   Clotet, Bonaventura ^a,e   Videla, Sebastian ^d  

^a Retrovirology Laboratory IrsiCaixa Foundation   (Spain)

^b SYNLAB ACADEMY   (Germany)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Lluita Contra la SIDA Foundation   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

HPV; HPV genotyping; Hybrid capture 2; Linear Array; Multiplex PCR; Test comparison

Indexed keywords

DNA;

ANALYTICAL EQUIPMENT; ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; FEMALE; GENOTYPE; HUMAN; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; VIRUS DETECTION; VIRUS EXAMINATION; WART VIRUS;

CERVIX UTERI; CLINICAL LABORATORY TECHNIQUES; FEMALE; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

EID: 84860567898     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.03.005     Document Type: Article

References (21)

1. Bosch F.X., de Sanjosé S. Human Paplillamavirus in cervical cancer. Curr. Oncol. Rep. 2002, 4:175-183.
2. Cañadas M.P., Videla S., Darwich L., Tarrats A., Piñol M., García-Cuyás F., Llatjos M., Alcalde C., Fernández I., Sirera G., Clotet B. Human papillomavirus-16, -18, -52 and -58 integration in cervical cells of HIV-1 infected women. J. Clin. Virol. 2010, 48:198-201.
3. Castle P.E., Lorincz A.T., Mielzynska-Lohnas I., Scott D.R., Glass A.G., Sherman M.E., Schussler J.E., Schiffman M. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol. 2002, 40:1088-1090.
4. Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 2005, 97(July (14)):1066-1071.
5. Dalstein V., Merlin S., Bali C., Saunier M., Dachez R., Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J. Virol. Methods 2009, 156(March (1-2)):77-83.
6. Darwich L., Cañadas M.P., Sirera G., Alameda F., Forcada P., Delas J., Fernández I., Llatjós M., Coll J., Clotet B., Videla S. Human papillomavirus genotype distribution and human papillomavirus 16 and human papillomavirus 18 genomic integration in invasive and in situ cervical carcinoma in human immunodeficiency virus-infected women. Int. J. Gynecol. Cancer 2011, (November).
7. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., Tous S., Felix A., Bravo L.E., Shin H.R., Vallejos C.S., de Ruiz P.A., Lima M.A., Guimera N., Clavero O., Alejo M., Llombart-Bosch A., Cheng-Yang C., Tatti S.A., Kasamatsu E., Iljazovic E., Odida M., Prado R., Seoud M., Grce M., Usubutun A., Jain A., Suarez G.A., Lombardi L.E., Banjo A., Menéndez C., Domingo E.J., Velasco J., Nessa A., Chichareon S.C., Qiao Y.L., Lerma E., Garland S.M., Sasagawa T., Ferrera A., Hammouda D., Mariani L., Pelayo A., Steiner I., Oliva E., Meijer C.J., Al-Jassar W.F., Cruz E., Wright T.C., Puras A., Llave C.L., Tzardi M., Agorastos T., Garcia-Barriola V., Clavel C., Ordi J., Andújar M., Castellsagué X., Sánchez G.I., Nowakowski A.M., Bornstein J., Muñoz N., Bosch F.X. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11(November (11)):1048-1056. Retrospective International Survey, HPV Time Trends Study Group, (Epub 2010 Oct 15).
8. Depuydt C.E., Boulet G.A., Horvath C.A., Benoy I.H., Vereecken A.J., Bogers J.J. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J. Cell. Mol. Med. 2007, 11(July-August (4)):881-891.
9. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheele r C.M., Coutlée F., Hildesheim A., Schiffman M.H., Scott D.R., Apple R.J. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 2000, 38:357-361.
10. Gustavsson I., Juko-Pecirep I., Backlund I., Wilander E., Gyllensten U. Comparison between the hybrid capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J. Clin. Virol. 2009, 45(June (2)):85-89.
11. Heymans J., Benoy I.H., Poppe W., Depuydt C.E. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int. J. Cancer 2010, (November).
12. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 2005, 20:1072-1079.
13. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., Suntum M., Bock J.E., Poll P.A., Meijer C.J. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325(7364):572. 14.
14. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348(February (6)):518-527. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.
15. Nobbenhuis M.A., Meijer C.J., van den Brule A.J., Rozendaa l L., Voorhorst F.J., Risse E.K., Verheijen R.H., Helmerhorst T.J. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer 2001, 23:796-801.
16. Parkin D.M., Bray F.I., Devessa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001, 37(Suppl. 8):S4-S66.
17. Perrons C., Jelley R., Kleter B., Quint W., Brink N. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J. Clin. Virol. 2005, 32:278-285.
18. Sandri M.T., Lentati P., Benini E., Dell'Orto P., Zorzino L., Carozzi F.M., Maisonneuve P., Passerini R., Salvatici M., Casadio C., Boveri S., Sideri M. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 2006, 44(June (6)):2141-2146.
19. Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G., Mielzynska-Lohnas I., Rush B.B., Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 2003, 95:46-52.
20. Videla S., Darwich L., Cañadas M.P., Paredes R., Tarrats A., Castella E., Llatjos M., Bofill M. Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology. J. Acquir. Immune Defic. Syndr. 2009, 50(2):168-175.
21. Walboomers M.M., Jacobs M.V., Manos M.M., Bosch X., Kummer A., Shah K.V. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.